Tango Therapeutics insider sells 27K shares

Q: What insider transactions did TNGX report for Crystal Adam on September 1, 2026?

Crystal Adam exercised 27,000 stock options for Tango Therapeutics common stock at an exercise price of $5.20 per share and sold 27,000 shares of common stock at a weighted average price of $22.367 per share, all on September 1, 2026.

Q: What prices were involved in Crystal Adam’s Tango Therapeutics (TNGX) trades?

The stock options were exercised at $5.20 per share. The 27,000 shares sold had a weighted average sales price of $22.367 per share, with individual sale prices ranging from $22.08 to $22.86 per share.

Q: What is the vesting schedule of the Tango Therapeutics options exercised by Crystal Adam?

The option vests over four years: 25% vested on February 27, 2024, and the remaining shares vest in 36 equal monthly installments thereafter, according to the disclosure.

Q: When do Crystal Adam’s Tango Therapeutics options involved in this Form 4 expire?

The stock option series from which 27,000 options were exercised has an expiration date of March 1, 2033, as stated in the filing.

Tango Therapeutics’ R&D president exercised options and sold 27,000 shares in pre-planned trades under a Rule 10b5-1 plan.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Tango Therapeutics, Inc. (TNGX) reported that Crystal Adam, President, R&D, exercised stock options for 27,000 shares of common stock on September 1, 2026 at an exercise price of $5.20 per share and sold 27,000 shares at a weighted average price of $22.367 per share. These transactions were effected under a Rule 10b5-1 trading plan adopted on October 27, 2025. Following the option exercise, Adam held 260,040 stock options directly, which remain outstanding and exercisable through their stated expiration, subject to the vesting schedule.

Insider Trade Summary 10b5-1

Exercise and Sale: 27,000 shares ($464K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Crystal Adam

Role President, R&D

Sold 27,000 shs ($604K)

Approx. gross sale proceeds $604K

Approx. exercise cost $140K

Approx. pre-tax spread $464K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^{F1, F3}	27,000	$0.00	$0.00
Exercise	Common Stock ^F1	27,000	$5.20	$140K
Sale	Common Stock ^{F1, F2}	27,000	$22.367	$604K

Holdings After Transaction: Stock Option (Right to Buy) — 260,040 contracts (Direct); Common Stock — 115,743 shares (Direct)

Footnotes (3)

F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $22.08 to $22.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Key Figures

Options exercised: 27,000 shares Exercise price: $5.20 per share Shares sold: 27,000 shares +4 more

7 metrics

Options exercised 27,000 shares Stock options for Tango Therapeutics common stock exercised on September 1, 2026

Exercise price $5.20 per share Price paid to exercise the 27,000 stock options

Shares sold 27,000 shares Common stock sold on September 1, 2026

Weighted average sale price $22.367 per share Sales prices ranged from $22.08 to $22.86 per share

Options held after transaction 260,040 options Stock options held directly by Crystal Adam following the exercise

Option expiration date March 1, 2033 Expiration of the option series from which 27,000 shares were exercised

Rule 10b5-1 plan adoption date October 27, 2025 Adoption date of the trading plan governing these transactions

Key Terms

Rule 10b5-1 trading plan, weighted average sales price per share, vest and become exercisable, monthly installments

4 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

vest and become exercisable financial

"This option shall vest and become exercisable over a four-year period"

monthly installments financial

"with the remaining option shares vesting in 36 equal monthly installments thereafter."

Monthly installments are regular, fixed payments made each month to gradually pay off a larger amount, such as a loan or purchase. Think of it like paying for a big item in small, manageable parts instead of all at once. For investors, understanding installment payments helps gauge how debts are structured and how they might affect financial stability or cash flow over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did TNGX report for Crystal Adam on September 1, 2026?

Crystal Adam exercised 27,000 stock options for Tango Therapeutics common stock at an exercise price of $5.20 per share and sold 27,000 shares of common stock at a weighted average price of $22.367 per share, all on September 1, 2026.

Were Crystal Adam’s TNGX transactions made under a Rule 10b5-1 plan?

Yes. The filing states that these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025, indicating the trades were pre-arranged under that plan.

What prices were involved in Crystal Adam’s Tango Therapeutics (TNGX) trades?

The stock options were exercised at $5.20 per share. The 27,000 shares sold had a weighted average sales price of $22.367 per share, with individual sale prices ranging from $22.08 to $22.86 per share.

How many Tango Therapeutics options does Crystal Adam hold after these transactions?

After exercising options on September 1, 2026, Crystal Adam held 260,040 stock options for Tango Therapeutics common stock directly, as reported in the filing.

What is the vesting schedule of the Tango Therapeutics options exercised by Crystal Adam?

The option vests over four years: 25% vested on February 27, 2024, and the remaining shares vest in 36 equal monthly installments thereafter, according to the disclosure.

When do Crystal Adam’s Tango Therapeutics options involved in this Form 4 expire?

The stock option series from which 27,000 options were exercised has an expiration date of March 1, 2033, as stated in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/03/2026 - 04:01 PM EDT Accepted by SEC EDGAR 09/03/2026 - 04:01 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crystal Adam

(Last)

(First)

(Middle)

C/O TANGO THERAPEUTICS, INC.,

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON

MASSACHUSETTS

02215

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/01/2026		M⁽¹⁾		27,000	A	$5.2	142,743	D
Common Stock	09/01/2026		S⁽¹⁾		27,000	D	$22.367⁽²⁾	115,743	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$5.2	09/01/2026		M⁽¹⁾			27,000	⁽³⁾	03/01/2033	Common Stock	27,000	$0	260,040	D

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $22.08 to $22.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

	/s/ Julie Fogarty, as attorney-in-fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR